Keyphrases
3D Endoanal Ultrasound
15%
5-aminosalicylic Acid (5-ASA)
15%
Adalimumab
34%
Adherence to Therapy
15%
Anti-adalimumab Antibodies
31%
Antibody Formation
16%
Capsule Endoscopy
31%
Clinical Activity
17%
Clinical Response
22%
Confidence Interval
29%
Corticosteroids
34%
Crohn's Disease
100%
Crowdsourcing
15%
Cytomegalovirus
15%
Diagnostic Performance
19%
Drug Concentration
15%
Fecal Calprotectin
15%
Hospitalized Patients
17%
Immunogenicity
22%
Immunomodulator
19%
Inflammatory Bowel Disease
51%
Loss of Response
16%
Low Albumin
17%
Magnetic Resonance Enterography
15%
Meta-analysis
35%
Narrow Band Imaging
15%
Neoplasia
15%
Neutrophil-to-lymphocyte Ratio
15%
Non-adherence
15%
Novel Biomarkers
15%
Odds Ratio
30%
Phrasing
15%
Place in Therapy
15%
Poeticity
15%
Pooled Analysis
31%
Randomized Controlled Trial
18%
Real-world Experience
28%
Reporting Odds Ratio
15%
Simple Tools
15%
Small Bowel Adenocarcinoma
15%
Small Bowel Crohn's Disease
31%
Small Intestine
18%
Syndecan-1
15%
Systematic Meta-analysis
62%
Three-dimensional Endoanal Ultrasound
15%
Time Dependency
15%
Treatment Efficacy
15%
Ustekinumab
34%
Vedolizumab
21%
Web Platform
15%
Medicine and Dentistry
Acute Pancreatitis
15%
Adalimumab
15%
Adenocarcinoma
15%
Adverse Event
7%
Aminosalicylic Acid Derivative
15%
Biological Marker
16%
Calgranulin
7%
Capsule Endoscopy
31%
Cerebral Sinus Thrombosis
15%
Chromoendoscopy
15%
Combination Therapy
5%
Coronavirinae
15%
Corticosteroid Therapy
15%
Crohn's Disease
62%
Cytomegalovirus
15%
Diagnosis
36%
Diagnostic Accuracy
5%
Disease
15%
Faecal Calprotectin
15%
Feces Incontinence
11%
Hip Fracture
15%
Ibuprofen
15%
Immunomodulating Agent
18%
Infection
10%
Inflammatory Bowel Disease
41%
Injury
7%
Internal Anal Sphincter
15%
Lymphocyte
15%
Magnetic Resonance Enterography
15%
Meta-Analysis
35%
Mortality Rate
6%
Muscle Disease
7%
Muscle Injury
7%
Narrow Band Imaging
15%
Neoplasm
15%
Neutrophil
15%
Nilotinib
15%
Odds Ratio
38%
Pancreas Adenocarcinoma
15%
Patient with Inflammatory Bowel Disease
17%
Pooled Analysis
15%
Rehabilitation Engineering
15%
Retrospective Study
6%
Salvage Therapy
7%
Syndecan 1
15%
Systematic Review
46%
Thrombosis
9%
Ulcerative Colitis
31%
Vedolizumab
15%
White Light Endoscopy
15%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Pancreatitis
15%
Adalimumab
31%
Adverse Event
12%
Aminosalicylic Acid
31%
Biological Product
10%
Combination Therapy
8%
Coronavirinae
15%
Crohn's Disease
70%
Disease
20%
Disease Course
5%
Drug Concentration
15%
Enteropathy
15%
Hip Fracture
15%
Ibuprofen
15%
Immunogenicity
19%
Immunomodulating Agent
18%
Infection
12%
Inflammation
15%
Inflammatory Bowel Disease
50%
Infliximab
8%
Mortality Rate
7%
Nilotinib
15%
Pancreatitis
5%
Prospective Study
15%
Randomized Controlled Trial
18%
Remission
11%
Ulcerative Colitis
51%
Ustekinumab
31%
Vedolizumab
15%
